CytoDyn Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYDY research report →
Price Chart
About the company
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor.
- CEO
- Jacob Lalezari
- IPO
- 2006
- Employees
- 14
- HQ
- Vancouver, WA, US
Get TickerSpark's AI analysis on CYDY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $273.95M
- P/E
- -5.83
- PEG
- 0.03
- P/S
- 0.00
- P/B
- -2.50
- EV/EBITDA
- -7.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 39.42%
- ROIC
- 57.70%
Latest fiscal year · YoY change
- Revenue
- $0+100.0%
- Gross Profit
- $-17,000+5.6%
- Op Income
- $-21,811,000
- Net Income
- $-42,699,000-1240.2%
- EPS
- $-0.03-1905.3%
- OCF Growth
- -96.8%
- FCF Growth
- -96.8%
- 52W High
- $0.40
- 52W Low
- $0.18
- 50D MA
- $0.21
- 200D MA
- $0.26
- Beta
- 1.24
- RSI (14)
- 44
- Avg Volume
- 1.56M
No earnings-call transcripts are available for CYDY yet.
- Free Float
- 99.7%
- Shares Outstanding
- 1.47B
- Float Shares
- 1.37B
of shares held by institutions
9 13F filers
Buy/sell ratio 1.71. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Diversified Trust Co | 45.79K | 0 |
| Williams Jones Wealth Management, LLC. | 45.00K | 0 |
| Next Capital Management LLC | 25.00K | 0 |
| Horizon Financial Services, LLC | 18.20K | 0 |
| Ancora Advisors, LLC | 9.49K | 0 |
| Caz Investments LP | 4.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Urbach Tanya Durkee | other | 574,385 |
| Mar 20, 26 | SIMES STEPHEN M | other | 574,385 |
| Mar 20, 26 | Ndhlovu Lishomwa C | other | 574,385 |
| Mar 20, 26 | Lalezari Jacob P | other | 4,874,691 |
| Mar 20, 26 | Hoffman Robert E. | other | 4,874,691 |
| Mar 20, 26 | Dunlap Ryan | other | 574,385 |
| Mar 20, 26 | Brunke Karen J | other | 574,385 |
| Mar 20, 26 | Blok Tyler | other | 3,249,794 |
| May 15, 25 | Hoffman Robert E. | other | 1,000,000 |
| May 15, 25 | Hoffman Robert E. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYDY coverage
Recent articles, reports, and earnings notes.
No research on CYDY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYDY report →CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
globenewswire.com · Oct 8
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
marketbeat.com · Sep 19
CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
defenseworld.net · Sep 18
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
globenewswire.com · Sep 15
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
globenewswire.com · Sep 1
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
prnewswire.com · Jul 22
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
globenewswire.com · Jun 11
CytoDyn to Present at the LD Micro Invitational XVI
globenewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.